Palatin Technologies, Inc.(NYSE Amex Equities : PTN)
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading PTN News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.06%||67.06||1.0%||$564.12m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.14%||383.10||2.1%||$349.89m|
|KITE||Kite Pharma, Inc.||0.00%||78.61||17.5%||$217.46m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.00%||118.53||1.6%||$201.95m|
|VRTX||Vertex Pharmaceuticals Incorporated||19.85%||107.47||2.0%||$160.67m|
|ESPR||Esperion Therapeutics, Inc.||1.96%||36.36||17.7%||$152.95m|
|CLVS||Clovis Oncology, Inc.||0.00%||67.06||17.2%||$140.22m|
|AUPH||Aurinia Pharmaceuticals Inc.||0.70%||7.21||8.0%||$131.34m|
Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.